ABUS
NASDAQ
US
Arbutus Biopharma Corporation - Common Stock
$4.48
▼ $-0.04
(-0.89%)
Vol 612K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$925.1M
ROE
-50.2%
Margin
-289.5%
D/E
0.00
Beta
0.72
52W
$3–$5
Wall Street Consensus
9 analysts · Apr 20263
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 60.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.04 | $-0.02 | +$0.02 |
| Sep 2025 | $-0.03 | $-0.04 | $-0.01 |
| Jun 2025 | $-0.05 | $0.01 | +$0.06 |
| Mar 2025 | $-0.11 | $-0.13 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $1.3M | $1.6M | $1.8M | $10.7M | $529K |
| Net Income | -$19.7M | -$12.5M | -$24.5M | $2.5M | -$7.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -59.2% | -59.2% | -59.2% | -59.2% | -59.2% | -50.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 23.5% | -351.9% | -351.9% | -351.9% | -351.9% | -289.4% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 20.53 | 20.53 | 20.53 | 20.53 | 20.53 | 18.80 |
Key Ratios
ROA (TTM)
-37.6%
P/S (TTM)
63.34
P/B
6.4
EPS (TTM)
$-0.22
CF/Share
$-0.46
Rev Growth 3Y
-17.5%
52W High
$5.10
52W Low
$2.71
$2.71
52-Week Range
$5.10
Financial Health
Free Cash Flow
-$5.8M
Net Debt
-$21.5M
Cash
$22.4M
Total Debt
$922K
As of Sep 30, 2025
How does ABUS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ABUS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
63.3
▲
393%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
6.4
▲
159%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ABUS profitability vs Biotechnology peers
ROE
-50.2%
▲
25%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-289.5%
▼
1%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-37.6%
▲
19%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
ABUS financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
18.8
▲
323%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.7
▼
25%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ABUS fundamentals radar
ABUS
Peer median
Industry
ABUS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ABUS vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
ANDROSKI LINDSAY J.D.
Chief Executive Officer · Feb 02
28000 shs
NGUYEN TUAN
Chief Financial Officer · Feb 02
73500 shs
Last 90 days
Top Holders
Top 5: 38.97%Morgan Stanley
13.88%
$114.6M
Whitefort Capital Managemen…
6.94%
$57.2M
Blackrock Inc.
6.79%
$56.0M
Two Seas Capital Lp
6.55%
$54.0M
Vanguard Group Inc
4.81%
$39.7M
As of Dec 31, 2025